Holen Sie sich die Stockscreener-App
36.17
2.64%
0.93
Handel nachbörslich:
36.88
0.71
+1.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$35.24
Offen:
$35.71
24-Stunden-Volumen:
974.26K
Relative Volume:
0.77
Marktkapitalisierung:
$2.12B
Einnahmen:
$238.11M
Nettoeinkommen (Verlust:
$-31.45M
KGV:
-57.10
EPS:
-0.6334
Netto-Cashflow:
$7.66M
1W Leistung:
+0.00%
1M Leistung:
-18.22%
6M Leistung:
-2.85%
1J Leistung:
+113.14%
1-Tages-Spanne:
$35.56
$36.84
1-Wochen-Bereich:
$34.11
$36.84
52-Wochen-Spanne:
$16.65
$52.91
Axogen Inc Stock (AXGN) Company Profile
Firmenname
Axogen Inc
Sektor
Branche
Telefon
(386) 462-6817
Adresse
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
36.17 | 2.12B | 238.11M | -31.45M | 7.66M | -0.6334 |
ABT
Abbott Laboratories
|
102.45 | 177.28B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.63 | 121.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
304.40 | 116.76B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.58 | 66.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.29 | 50.89B | 6.30B | 1.07B | 1.09B | 1.8406 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Eingeleitet | BofA Securities | Buy |
| 2026-10-07 | Eingeleitet | Barclays | Overweight |
| 2026-08-26 | Eingeleitet | Truist | Buy |
| 2026-02-19 | Eingeleitet | Wells Fargo | Overweight |
| 2025-12-01 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Lake Street | Buy |
| 2024-07-01 | Eingeleitet | Raymond James | Outperform |
| 2022-11-11 | Fortgesetzt | Jefferies | Buy |
| 2022-05-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-06-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-03-02 | Bestätigt | Lake Street | Buy |
| 2018-01-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Eingeleitet | Jefferies | Buy |
| 2017-11-21 | Bestätigt | Lake Street | Buy |
| 2017-07-31 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Eingeleitet | ROTH Capital | Buy |
| 2016-11-22 | Hochstufung | Lake Street | Hold → Buy |
| 2016-11-07 | Bestätigt | Wedbush | Outperform |
| 2016-11-03 | Herabstufung | Lake Street | Buy → Hold |
| 2016-08-04 | Bestätigt | Wedbush | Outperform |
| 2014-05-14 | Eingeleitet | Dawson James | Buy |
| 2013-10-31 | Bestätigt | Ladenburg Thalmann | Buy |
Alle ansehen
Axogen Inc Aktie (AXGN) Neueste Nachrichten
GMED or AXGN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) - Zacks Investment Research
A passive stake above 5% in Axogen (AXGN) is held through advisory clients. - Stock Titan
AXGN | Axogen, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Axogen, Inc.Common Stock (Nasdaq:AXGN) Stock Quote - The Chronicle-Journal
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover - Yahoo Finance
Axogen announces pricing of public offering - medicalbuyer.co.in
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors - GuruFocus
AXGN 424B FilingsAxogen Inc SEC 424B - Stock Titan
Axogen To Acquire BioCircuit Technologies For $200 Million To Add Sutureless Nerve Repair Platform - Pulse 2.0
Why Is Axogen Stock Tumbling Today?Axogen (NASDAQ:AXGN) - Benzinga
Axogen to buy BioCircuit Technologies for $200M - medtechdive.com
Axogen Announces $200 Million Acquisition of BioCircuit Technologies Alongside $42.50 Per Share Stock Offering - Kalkine Media
Axogen to acquire Biocircuit for $200M - BioWorld News
2 Medical-Device Stocks Lighting Up the Options Pits - schaeffersresearch.com
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com South Africa
Axogen stock falls as $208.7M offering dilutes shareholders By Investing.com - Investing.com Australia
Axogen stock falls as $208.7M offering dilutes shareholders - investing.com
Why is Axogen stock sliding today? By Investing.com - Investing.com South Africa
Axogen stock falls as $208.7M offering dilutes shareholders - Investing.com
Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition - citybiz
Axogen to Acquire BioCircuit Technologies in $200 Million Nerve Repair Deal - citybiz
Why is Axogen stock sliding today? By Investing.com - Investing.com Canada
Why is Axogen stock sliding today? - investing.com
Axogen acquires BioCircuit Technologies for $200 million - grafa.com
Axogen Announces Pricing Of $208.7 Million Public Offering Of Common Stock - TradingView
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio - TipRanks
Axogen prices $208.7 million stock offering at $42.50 per share - investing.com
AXGN Looks 171.8% Overvalued on GF Value™ - GuruFocus
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com India
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com Canada
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com India
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - manilatimes.net
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Canada
Axogen Prices $208.7 Million Public Offering of Common Stock to Help Fund BioCircuit Acquisition - Quiver Quantitative
AXGN: Acquisition of a pioneering sutureless nerve repair device is expected to drive growth and innovation - TradingView
Axogen to acquire BioCircuit for $200M, adds nerve repair device - Investing.com UK
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies - GlobeNewswire
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com South Africa
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - globenewswire.com
Nerve repair without stitches is at the center of Axogen’s $200 million deal - Stock Titan
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - Yahoo Finance
Axogen to Acquire BioCircuit Technologies for $200 Million - Yahoo Finance
The first FDA-cleared device to repair cut nerves without stitches is now part of Axogen. - Stock Titan
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - The Manila Times
Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million. - marketscreener.com
Understanding the Setup: (AXGN) and Scalable Risk - Stock Traders Daily
Axogen Director Tyndall Joseph A. Disposes of 3,500 Shares at $49.70 Each - Kalkine Media
Finanzdaten der Axogen Inc-Aktie (AXGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axogen Inc-Aktie (AXGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| JOSEPH A TYNDALL | Director |
Sep 02 '26 |
Proposed Sale |
49.88 |
3,500 |
174,580 |
0 |
| Wendell Amy McBride | Director |
Aug 11 '26 |
Option Exercise |
14.85 |
13,353 |
198,292 |
121,329 |
| Wendell Amy McBride | Director |
Aug 11 '26 |
Sale |
48.42 |
13,353 |
646,592 |
107,976 |
| AMY MCBRIDE-WENDELL | Director |
Aug 11 '26 |
Proposed Sale |
48.22 |
13,353 |
643,882 |
0 |
| Began Marc A | EVP & General Counsel |
Aug 10 '26 |
Sale |
47.34 |
67,500 |
3,195,788 |
50,135 |
| MARC BEGAN | Officer |
Aug 10 '26 |
Proposed Sale |
46.43 |
67,500 |
3,134,025 |
0 |
| Began Marc A | EVP & General Counsel |
Aug 10 '26 |
Option Exercise |
8.16 |
67,500 |
550,800 |
117,635 |
| KATHY WEILER | Director |
Aug 07 '26 |
Proposed Sale |
44.35 |
14,150 |
627,552 |
0 |
| Weiler Kathy Johnson | Director |
Aug 07 '26 |
Sale |
45.30 |
14,150 |
640,967 |
0 |
| Wendell Amy McBride | Director |
Jun 19 '26 |
Option Exercise |
0.00 |
14,150 |
0 |
107,976 |
1.70%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):